Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials

Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials

Background. Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) (nabiximols or Sativex®) is an oromucosal spray formulation containing THC and CBD at an approximately 1:1 fixed ratio. Its administration for the treatment of pain in patients with multiple sclerosis (MS) has been established....

Full description

Bibliographic Details
Main Authors: Mara Turri, Francesco Teatini, Francesco Donato, Giampietro Zanette, Valeria Tugnoli, Luciano Deotto, Bruno Bonetti, Giovanna Squintani
Format: Article
Language:English
Published: MDPI AG 2018-06-01
Series:Medicines
Subjects:
pain
multiple sclerosis
oromucosal cannabinoid spray
quantitative sensory testing
laser-evoked potentials
Online Access:http://www.mdpi.com/2305-6320/5/3/59

Internet

http://www.mdpi.com/2305-6320/5/3/59

Similar Items